Day 1: Tuesday September 16Tuesday, 16 September 2025

Reviewing the unprecedented growth of the obesity therapeutics market, as obesity is recognized a complex chronic disease. Highlighting current approaches, strategies and partnerships driving innovation in the field.

• What modalities are empowering the growth of the obesity therapeutics market?

• What new targets is the industry looking at beyond GLP-1R?

• What next steps must be taken to accelerate patient adherence and reduce side effects of weight-loss drugs?

• How can appetite suppressing and energy expenditure drugs be synergized?

• Highlighting the most impactful collaborations from the past year

• Which approaches and targets are pharma looking at most?

• How are pharma evaluating potential partnerships with early-stage biotech and academia?

• Exploring a dual GCGR/GLP-1 peptide agonist in patients with obesity as well as MASH, highlighting key developments from Phase 2 (Obesity) and Phase 3 (MASH) trials

• Highlighting increased potency benefits of dual agonism approach

• Exploring updates on oral small molecule GLP-1R candidate, RGT-075, as it progresses through Phase 2b clinical trials
• Insight into the rCARDTM propriety platform to enable accelerated drug discovery within obesity therapeutics

• Highlighting opportunities for improved tolerability and preservation of lean muscle mass in patients

• Sharing clinical insights into a once-weekly subcutaneously administered amylin analog for weight-loss and improved glucose metabolism

• Outlining the formulation of a next generation oral tablet GLP-1 therapy for increased adherence within obesity and type 2 diabetes patients

• Exploring Phase 1 clinical data of KAI-7535

• DA-1726 is being developed by MetaVia Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist with a 3:1 GLP1R to GCGR ratio.

• OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists.

• In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction.

• Utilising a unique triple monoamine reuptake inhibitor, tesofensine, to increase brain levels of dopamine, serotonin and noradrenaline for regulation of food seeking behaviour

• Highlighting Phase 3 clinical updates

• Developing a GLP-1 agonist-ActR2A/B monoclonal antibody conjugate for adipose specific weight loss alongside maintained skeletal muscle mass

• Exploring pre-clinical updates, as well as insight into further weight-loss drug conjugates beyond GLP-1 agonists

• Advancing RJx-01, an innovative small molecule combination drug to impact muscle strength loss in sarcopenia
• Potential to address sarcopenia associated with obesity treatment in older obese people and sarcopenia obesity
• Accelerating development process via CombinAge™ and CelegAge™ proprietary discovery platforms

Pioneering a transformative approach to obesity treatment through locally administered Adeno-Associated Virus (AAV) gene therapy, designed to provide long-lasting weight management solutions by targeting specific metabolic pathways and integrating GLP-1-secreting transgenes directly into pancreatic beta islet cells